Exact Sciences Corp. (EXAS): Price and Financial Metrics

Exact Sciences Corp. (EXAS): $71.01

4.13 (+6.18%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

EXAS Price/Volume Stats

Current price $71.01 52-week high $100.77
Prev. close $66.88 52-week low $56.05
Day low $67.18 Volume 3,393,179
Day high $71.62 Avg. volume 1,991,712
50-day MA $61.91 Dividend yield N/A
200-day MA $72.75 Market Cap 12.89B

EXAS Stock Price Chart Interactive Chart >

EXAS POWR Grades

  • EXAS scores best on the Growth dimension, with a Growth rank ahead of 90.18% of US stocks.
  • EXAS's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
  • EXAS's current lowest rank is in the Momentum metric (where it is better than 7.41% of US stocks).

EXAS Stock Summary

  • EXAS has a higher market value than 85.3% of US stocks; more precisely, its current market capitalization is $12,648,645,083.
  • Price to trailing twelve month operating cash flow for EXAS is currently 91.26, higher than 96.86% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 5.26, EXACT SCIENCES CORP has a higher such ratio than 79.87% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to EXACT SCIENCES CORP are OMCL, SSTI, YEXT, REFR, and AXGN.
  • Visit EXAS's SEC page to see the company's official filings. To visit the company's web site, go to www.exactsciences.com.

EXAS Valuation Summary

  • EXAS's EV/EBIT ratio is -58.1; this is 497.95% lower than that of the median Healthcare stock.
  • Over the past 243 months, EXAS's EV/EBIT ratio has gone down 52.3.

Below are key valuation metrics over time for EXAS.

Stock Date P/S P/B P/E EV/EBIT
EXAS 2023-12-29 5.6 4.3 -47.4 -58.1
EXAS 2023-12-28 5.7 4.4 -48.5 -59.3
EXAS 2023-12-27 5.7 4.4 -48.5 -59.2
EXAS 2023-12-26 5.7 4.4 -48.5 -59.2
EXAS 2023-12-22 5.5 4.3 -47.1 -57.7
EXAS 2023-12-21 5.4 4.1 -45.8 -56.3

EXAS Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -119.8%.
  • Its 3 year revenue growth rate is now at 251.87%.
  • The 5 year cash and equivalents growth rate now stands at 1688.13%.
EXAS's revenue has moved up $1,951,375,000 over the prior 70 months.

The table below shows EXAS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 2,084.279 -223.559 -623.506
2022-09-30 2,005.096 -300.168 -716.372
2022-06-30 1,938.402 -300.016 -734.549
2022-03-31 1,851.581 -198.763 -745.398
2021-12-31 1,767.087 -102.236 -595.625
2021-09-30 1,759.614 33.74 -811.824

EXAS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EXAS has a Quality Grade of D, ranking ahead of 24.25% of graded US stocks.
  • EXAS's asset turnover comes in at 0.281 -- ranking 445th of 561 Business Services stocks.
  • ISGN, ADBE, and FTAI are the stocks whose asset turnover ratios are most correlated with EXAS.

The table below shows EXAS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.281 0.750 -0.310
2021-06-30 0.301 0.755 -0.344
2021-03-31 0.302 0.752 -0.332
2020-12-31 0.328 0.762 -0.274
2020-09-30 0.315 0.755 -0.171
2020-06-30 0.319 0.751 -0.126

EXAS Price Target

For more insight on analysts targets of EXAS, see our EXAS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $148.88 Average Broker Recommendation 1.28 (Strong Buy)

Exact Sciences Corp. (EXAS) Company Bio


Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer. (Source:Wikipedia)


EXAS Latest News Stream


Event/Time News Detail
Loading, please wait...

EXAS Latest Social Stream


Loading social stream, please wait...

View Full EXAS Social Stream

Latest EXAS News From Around the Web

Below are the latest news stories about EXACT SCIENCES CORP that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 31% Below Their Intrinsic Value Estimate

Key Insights The projected fair value for Exact Sciences is US$107 based on 2 Stage Free Cash Flow to Equity Exact...

Yahoo | December 25, 2023

Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.

Yahoo | December 21, 2023

1 Supercharged Growth Stock to Buy Before It Soars as Much as 222%, According to Cathie Wood's Ark Invest

If the fund manager's calculations prove to be correct, shareholders could enjoy threefold returns over the coming four years. Is she right?

Yahoo | December 17, 2023

Ark Invest Stock Portfolio: 16 Biggest Positions

In this article, we discuss the 16 biggest positions in the ARK Invest portfolio. If you want to read about some more stocks in the ARK Invest portfolio, go directly to Ark Invest Stock Portfolio: 5 Biggest Positions. Catherine D. Wood, although relatively new to the industry, stands out as a somewhat controversial hedge fund […]

Yahoo | December 14, 2023

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.

Yahoo | December 13, 2023

Read More 'EXAS' Stories Here

EXAS Price Returns

1-mo 24.80%
3-mo -4.01%
6-mo 4.09%
1-year 5.81%
3-year -40.74%
5-year -18.02%
YTD -4.01%
2023 49.42%
2022 -36.39%
2021 -41.26%
2020 43.26%
2019 46.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!